{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:05:45Z","timestamp":1792623945873,"version":"4.5.0"},"reference-count":141,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2026,2]]},"DOI":"10.2967\/jnumed.124.268339","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:40Z","timestamp":1764086440000},"page":"175-185","source":"Crossref","is-referenced-by-count":16,"title":["The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies"],"prefix":"10.2967","volume":"67","author":[{"given":"Konstantinos","family":"Chiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026020205350800000_67.2.175.1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"2026020205350800000_67.2.175.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2026020205350800000_67.2.175.3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"2026020205350800000_67.2.175.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0910-3"},{"key":"2026020205350800000_67.2.175.5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"2026020205350800000_67.2.175.6","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31824b211b"},{"key":"2026020205350800000_67.2.175.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2026020205350800000_67.2.175.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2026020205350800000_67.2.175.9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2026020205350800000_67.2.175.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0)"},{"key":"2026020205350800000_67.2.175.11","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e3181919a48"},{"key":"2026020205350800000_67.2.175.12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnen\/nlw026","article-title":"Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum","volume":"75","author":"Serrano-Pozo","year":"2016","journal-title":"J Neuropathol Exp Neurol."},{"key":"2026020205350800000_67.2.175.13","first-page":"452","article-title":"High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy","volume":"145","author":"Suzuki","year":"1994","journal-title":"Am J Pathol."},{"key":"2026020205350800000_67.2.175.14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2026020205350800000_67.2.175.15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn016"},{"key":"2026020205350800000_67.2.175.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.07.012"},{"key":"2026020205350800000_67.2.175.17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","article-title":"Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B","volume":"43","author":"Adamczuk","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350800000_67.2.175.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.109009"},{"key":"2026020205350800000_67.2.175.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114785"},{"key":"2026020205350800000_67.2.175.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2088-x"},{"key":"2026020205350800000_67.2.175.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2753-3"},{"key":"2026020205350800000_67.2.175.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4669"},{"key":"2026020205350800000_67.2.175.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-1051-z"},{"key":"2026020205350800000_67.2.175.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.2008"},{"key":"2026020205350800000_67.2.175.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.004"},{"key":"2026020205350800000_67.2.175.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.142109"},{"key":"2026020205350800000_67.2.175.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70044-9"},{"key":"2026020205350800000_67.2.175.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2026020205350800000_67.2.175.29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000150"},{"key":"2026020205350800000_67.2.175.30","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.9"},{"key":"2026020205350800000_67.2.175.31","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00259-019-04409-1","article-title":"Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid- neocortical deposition","volume":"46","author":"Ciarmiello","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350800000_67.2.175.32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","article-title":"Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes","volume":"72","author":"Schreiber","year":"2015","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.14283\/jpad.2024.122","article-title":"Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies","volume":"11","author":"Sperling","year":"2024","journal-title":"J Prev Alzheimers Dis."},{"key":"2026020205350800000_67.2.175.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6669"},{"key":"2026020205350800000_67.2.175.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"2026020205350800000_67.2.175.37","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","article-title":"Clinical Effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial","volume":"80","author":"Altomare","year":"2023","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2000"},{"key":"2026020205350800000_67.2.175.39","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00476-x"},{"key":"2026020205350800000_67.2.175.40","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318232a379"},{"key":"2026020205350800000_67.2.175.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.6.1158"},{"key":"2026020205350800000_67.2.175.42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv236"},{"key":"2026020205350800000_67.2.175.43","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31825018f7"},{"key":"2026020205350800000_67.2.175.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70191-6"},{"key":"2026020205350800000_67.2.175.45","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005303"},{"key":"2026020205350800000_67.2.175.46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.3.631"},{"key":"2026020205350800000_67.2.175.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0342-8"},{"key":"2026020205350800000_67.2.175.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.01.028"},{"key":"2026020205350800000_67.2.175.49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww027"},{"key":"2026020205350800000_67.2.175.50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado8076"},{"key":"2026020205350800000_67.2.175.51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa276"},{"key":"2026020205350800000_67.2.175.52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236224"},{"key":"2026020205350800000_67.2.175.54","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.55","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa180"},{"key":"2026020205350800000_67.2.175.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.09.042"},{"key":"2026020205350800000_67.2.175.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254961"},{"key":"2026020205350800000_67.2.175.58","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04496-0"},{"key":"2026020205350800000_67.2.175.59","first-page":"100","article-title":"FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols","volume":"4","author":"Rodriguez-Gomez","year":"2017","journal-title":"J Prev Alzheimers Dis."},{"key":"2026020205350800000_67.2.175.60","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195248"},{"key":"2026020205350800000_67.2.175.61","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27271"},{"key":"2026020205350800000_67.2.175.62","doi-asserted-by":"crossref","first-page":"e12372","DOI":"10.1002\/trc2.12372","article-title":"Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET","volume":"9","author":"Shuping","year":"2023","journal-title":"Alzheimers Dement Transl Res Clin Interv."},{"key":"2026020205350800000_67.2.175.63","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1038\/s41467-024-49258-1","article-title":"Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimers disease tauopathies","volume":"15","author":"Lindberg","year":"2024","journal-title":"Nat Commun."},{"key":"2026020205350800000_67.2.175.64","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25406"},{"key":"2026020205350800000_67.2.175.65","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.108"},{"key":"2026020205350800000_67.2.175.66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5732"},{"key":"2026020205350800000_67.2.175.67","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2028-17.2017"},{"key":"2026020205350800000_67.2.175.68","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimers disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350800000_67.2.175.69","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0204-z"},{"key":"2026020205350800000_67.2.175.70","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx243"},{"key":"2026020205350800000_67.2.175.71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13195-025-01868-7","article-title":"Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimers disease","volume":"17","author":"Malpetti","year":"2025","journal-title":"Alzheimers Res Ther."},{"key":"2026020205350800000_67.2.175.72","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jama.2025.7817","article-title":"Frequency and clinical outcomes associated with tau positron emission tomography positivity","volume":"334","author":"Moscoso","year":"2025","journal-title":"JAMA."},{"key":"2026020205350800000_67.2.175.74","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41593-025-02000-6","article-title":"Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid- status, APOE genotype and sex","volume":"28","author":"Ossenkoppele","year":"2025","journal-title":"Nat Neurosci."},{"key":"2026020205350800000_67.2.175.75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaneurol.2023.1323","article-title":"Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms","volume":"80","author":"Smith","year":"2023","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.76","first-page":"e70033","article-title":"Survey among experts on the future role of tau-PET in clinical practice and trials","volume":"16","author":"Vermeiren","year":"2024","journal-title":"Alzheimers Dement Diagn Assess Dis Monit."},{"key":"2026020205350800000_67.2.175.77","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338"},{"key":"2026020205350800000_67.2.175.78","unstructured":"Cho H Mundada NS Apostolova LG . Amyloid and tau-PET in early-onset AD: baseline data from the longitudinal early-onset Alzheimers disease study (LEADS). Alzheimers Dement. 2023;19."},{"key":"2026020205350800000_67.2.175.79","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268119"},{"key":"2026020205350800000_67.2.175.80","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14336"},{"key":"2026020205350800000_67.2.175.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"2026020205350800000_67.2.175.82","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7"},{"key":"2026020205350800000_67.2.175.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"2026020205350800000_67.2.175.84","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171595"},{"key":"2026020205350800000_67.2.175.85","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3749-6"},{"key":"2026020205350800000_67.2.175.86","doi-asserted-by":"crossref","unstructured":"Farrell ME Jiang S Schultz AP .; Alzheimers Disease Neuroimaging Initiative and the Harvard Aging Brain Study. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96:e619e631.","DOI":"10.1212\/WNL.0000000000011214"},{"key":"2026020205350800000_67.2.175.87","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","article-title":"Concordance between amyloid-PET quantification and real-world visual reads","volume":"82","author":"Zeltzer","year":"2025","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.09.001"},{"key":"2026020205350800000_67.2.175.89","unstructured":"Leuzy A Raket LL Villemagne VL . Harmonizing tau positron emission tomography in Alzheimers disease: the CenTauR scale and the joint propagation model. Alzheimers Dement J Alzheimers Assoc. July 2024."},{"key":"2026020205350800000_67.2.175.90","first-page":"e12454","article-title":"CenTauR: toward a universal scale and masks for standardizing tau imaging studies","volume":"15","author":"Villemagne","year":"2023","journal-title":"Alzheimers Dement Amst Neth."},{"key":"2026020205350800000_67.2.175.91","doi-asserted-by":"crossref","first-page":"118259","DOI":"10.1016\/j.neuroimage.2021.118259","article-title":"Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation","volume":"238","author":"Schwarz","year":"2021","journal-title":"Neuroimage."},{"key":"2026020205350800000_67.2.175.92","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimers disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat Aging."},{"key":"2026020205350800000_67.2.175.93","doi-asserted-by":"crossref","first-page":"fcae031","DOI":"10.1093\/braincomms\/fcae031","article-title":"Tau accumulation and its spatial progression across the Alzheimers disease spectrum","volume":"6","author":"St-Onge","year":"2023","journal-title":"Brain Commun."},{"key":"2026020205350800000_67.2.175.94","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"2026020205350800000_67.2.175.95","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2101"},{"key":"2026020205350800000_67.2.175.96","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3028"},{"key":"2026020205350800000_67.2.175.97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"2026020205350800000_67.2.175.98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"2026020205350800000_67.2.175.99","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"2026020205350800000_67.2.175.100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimers disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis."},{"key":"2026020205350800000_67.2.175.101","doi-asserted-by":"crossref","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","article-title":"Lecanemab demonstrates highly selective binding to A protofibrils isolated from Alzheimers disease brains","volume":"130","author":"Johannesson","year":"2024","journal-title":"Mol Cell Neurosci."},{"key":"2026020205350800000_67.2.175.102","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.48101\/ujms.v128.10316","article-title":"A light at the end of the tunnelfrom mutation identification to a potential treatment for Alzheimers disease","volume":"128","author":"Lannfelt","year":"2023","journal-title":"Ups J Med Sci."},{"key":"2026020205350800000_67.2.175.103","doi-asserted-by":"crossref","first-page":"e092094","DOI":"10.1002\/alz.092094","article-title":"Is there evidence for a continued benefit for long-term lecanemab treatment? A benefit\/risk update from long-term efficacy, safety and biomarker data","volume":"20","author":"Van Dyck","year":"2024","journal-title":"Alzheimers Dement."},{"key":"2026020205350800000_67.2.175.104","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"2026020205350800000_67.2.175.105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res Ther."},{"key":"2026020205350800000_67.2.175.106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ehpc.2018.07.007","article-title":"An autopsy case of amyloid -related angiitis with cognitive impairment, multiple infarcts and subcortical hemorrhage","volume":"14","author":"Watanabe","year":"2018","journal-title":"Hum Pathol Case Rep."},{"key":"2026020205350800000_67.2.175.107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"2026020205350800000_67.2.175.108","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2215148"},{"key":"2026020205350800000_67.2.175.109","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000480"},{"key":"2026020205350800000_67.2.175.110","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jnen\/nlae068","article-title":"Cerebral amyloid--related angiitis and iatrogenic cerebral amyloid angiopathy-related vasculitis: Implications for amyloid-related imaging abnormalities","volume":"83","author":"Castellani","year":"2024","journal-title":"J Neuropathol Exp Neurol."},{"key":"2026020205350800000_67.2.175.111","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol."},{"key":"2026020205350800000_67.2.175.112","doi-asserted-by":"crossref","first-page":"e209674","DOI":"10.1212\/WNL.0000000000209674","article-title":"Heed the warning signs to avoid serious ARIA","volume":"103","author":"Salloway","year":"2024","journal-title":"Neurology."},{"key":"2026020205350800000_67.2.175.113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.114","doi-asserted-by":"crossref","unstructured":"Giorgio J Blazhenets G Mejia Perez J . Robust associations with posterior predominant amyloid PET binding [abstract]. Presented at Alzheimers Association International Conference 2025; July 27, 2025; Toronto, Canada.","DOI":"10.1002\/alz70862_110218"},{"key":"2026020205350800000_67.2.175.115","doi-asserted-by":"crossref","unstructured":"Kennedy I Kim MJ Lu M . Association of occipital amyloid PET burden with ARIA-E: exploratory analyses in three clinical trials of donanemab [abstract]. Presented at: Alzheimers Association International Conference 2025; July 29, 2025; Toronto, Canada.","DOI":"10.1002\/alz70862_110828"},{"key":"2026020205350800000_67.2.175.116","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.27008","article-title":"Head-to-head comparison of tau and amyloid positron emission tomography visual reads for differential diagnosis of neurodegenerative disorders: an international, multicenter study","volume":"96","author":"Soleimani-Meigooni","year":"2024","journal-title":"Ann Neurol."},{"key":"2026020205350800000_67.2.175.117","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05311-5"},{"key":"2026020205350800000_67.2.175.118","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268119"},{"key":"2026020205350800000_67.2.175.119","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211532"},{"key":"2026020205350800000_67.2.175.120","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/alz.13735","article-title":"Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimers disease","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement."},{"key":"2026020205350800000_67.2.175.121","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA. Neurol."},{"key":"2026020205350800000_67.2.175.122","unstructured":"Battioui C Gueorguieva I Lu M Collins EC Sims JR Shcherbinin S . Baseline characteristics associated with achieving rapid amyloid plaque clearance following donanemab treatment [abstract]. Presented at: AD\/PD 2024; March 2024; Lisbon, Portugal."},{"key":"2026020205350800000_67.2.175.123","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"2026020205350800000_67.2.175.124","doi-asserted-by":"crossref","first-page":"e091966","DOI":"10.1002\/alz.091966","article-title":"Long-term effects of lecanemab on biomarkers of neurodegeneration in plasma","volume":"20","author":"Teunissen","year":"2024","journal-title":"Alzheimers Dement."},{"key":"2026020205350800000_67.2.175.125","first-page":"86","article-title":"Reliability of automated amyloid PET quantification: real-world validation of commercial tools against Centiloid Project method","volume":"11","author":"Kang","year":"2025","journal-title":"Tomogr Ann Arbor Mich."},{"key":"2026020205350800000_67.2.175.126","first-page":"e70163","article-title":"Evaluation of two clinical Centiloid analysis products for 18F-florbetapir PET in cognitively unimpaired elders","volume":"17","author":"DiFilippo","year":"2025","journal-title":"Alzheimers Dement Amst Neth."},{"key":"2026020205350800000_67.2.175.127","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00898-8"},{"key":"2026020205350800000_67.2.175.128","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20918029"},{"key":"2026020205350800000_67.2.175.129","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis."},{"key":"2026020205350800000_67.2.175.130","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00883-2"},{"key":"2026020205350800000_67.2.175.131","unstructured":"Barton ME . Results from TOGETHER, a Phase II study of bepranemab in prodromalmild AD [abstract]. Presented at: 17th Clinical Trials on Alzheimers Disease meeting; October 2024; Madrid, Spain."},{"key":"2026020205350800000_67.2.175.132","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.133","doi-asserted-by":"crossref","unstructured":"Warmenhoven N Salvad G Janelidze S . A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. October 2024:awae346.","DOI":"10.1101\/2024.07.02.24309629"},{"key":"2026020205350800000_67.2.175.134","doi-asserted-by":"crossref","first-page":"105504","DOI":"10.1016\/j.ebiom.2024.105504","article-title":"Disentangling relationships between Alzheimers disease plasma biomarkers and established biomarkers in patients of tertiary memory clinics","volume":"112","author":"Bluma","year":"2024","journal-title":"EBioMedicine."},{"key":"2026020205350800000_67.2.175.135","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022"},{"key":"2026020205350800000_67.2.175.136","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01822-2"},{"key":"2026020205350800000_67.2.175.137","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"2026020205350800000_67.2.175.138","doi-asserted-by":"crossref","first-page":"e70293","DOI":"10.1002\/alz.70293","article-title":"TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimers disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"2026020205350800000_67.2.175.139","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimers disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med."},{"key":"2026020205350800000_67.2.175.140","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02443-z"},{"key":"2026020205350800000_67.2.175.141","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:53Z","timestamp":1785269933000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.2967\/jnumed.124.268339"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268339","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}